Literature DB >> 29183252

Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.

Destin U Lenz1, Effie L Crutcher1, Elisa M Greene1,2.   

Abstract

Sexual dysfunction is a bothersome side effect of several medications, though it has not yet been reported with the use of ledipasvir/sofosbuvir for the treatment of hepatitis C. However, sexual dysfunction is a potentially unrecognized side effect of ledipasvir/sofosbuvir that could result in nonadherence and treatment failure. We report a case of a 42-year-old man with a sudden onset of sexual dysfunction with the initiation of ledipasvir/sofosbuvir for the treatment of hepatitis C. The patient had no prior history or risk factors for the development of sexual dysfunction. His symptoms resolved upon discontinuation of ledipasvir/sofosbuvir after a successful 12-week course. Clinicians should be aware that sexual dysfunction is a possible side effect of ledipasvir/sofosbuvir and educate patients appropriately. Adherence should be emphasized as the risks of untreated hepatitis C virus far outweigh transient sexual dysfunction.

Entities:  

Keywords:  Harvoni®; hepatitis C virus; ledipasvir/sofosbuvir; sexual dysfunction

Mesh:

Substances:

Year:  2017        PMID: 29183252     DOI: 10.1177/0897190017744421

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  1 in total

1.  Impact of sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimens on the male sexual function of patients with chronic hepatitis C.

Authors:  Salma Samir Omar; Walid Ismail Ellakany; Iman Mohamed Abdelmeniem
Journal:  Infez Med       Date:  2021-09-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.